ArticleCommunications chemistry2020
Developing scandium and yttrium coordination chemistry to advance theranostic radiopharmaceuticals.
Article in Communications chemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 36 citations in OpenAlex.
- Recent Advances in Rare Earth Element Recovery: Liquid-Liquid Extraction and Magnetophoretic Separation.Industrial & engineering chemistry research · 2025Review
- Bioleaching of lanthanum from nickel metal hydride dry battery using siderophores produced by Pseudomonas sp.World journal of microbiology & biotechnology · 2025Article
- Phosphonate-Based Aza-Macrocycle Ligands for Low-Temperature, Stable Chelation of Medicinally Relevant Rare Earth Radiometals and Radiofluorination.Journal of the American Chemical Society · 2024Article
- A first-in-class dual-chelator theranostic agent designed for use with imaging-therapy radiometal pairs of different elements.Chemical science · 2024Article
- Actinium chelation and crystallization in a macromolecular scaffold.Nature communications · 2024Article
- Antibody-drug conjugates in cancer therapy: innovations, challenges, and future directions.Archives of pharmacal research · 2024Review
- Metal-Ligand Interactions in Scandium Complexes with Radiopharmaceutical Applications.Inorganic chemistry · 2023Article
- Sc-HOPO: A Potential Construct for Use in Radioscandium-Based Radiopharmaceuticals.Inorganic chemistry · 2023Article
- Siderocalin fusion proteins enable a newRSC chemical biology · 2023Article
- Versatile Macrocyclic Platform for the Complexation of [Inorganic chemistry · 2022Article
- Hydroxypyridinone-Based Metal Chelators towards Ecotoxicity: Remediation and Biological Mechanisms.Molecules (Basel, Switzerland) · 2022Review
- In situ beam reduction of Pu(IV) and Bk(IV) as a route to trivalent transuranic coordination complexes with hydroxypyridinone chelators.Journal of synchrotron radiation · 2022Article
- Hydroxypyridinones as a Very Promising Platform for Targeted Diagnostic and Therapeutic Radiopharmaceuticals.Molecules (Basel, Switzerland) · 2021Review
- Production of scandium radionuclides for theranostic applications: towards standardization of quality requirements.EJNMMI radiopharmacy and chemistry · 2021Review
- Advances in preclinical evaluation of experimental antibody-drug conjugates.Cancer drug resistance (Alhambra, Calif.) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The octadentate siderophore analog 3,4,3-LI(1,2-HOPO), denoted 343-HOPO hereafter, is known to have high affinity for both trivalent and tetravalent lanthanide and actinide cations. Here we extend its coordination chemistry to the rare-earth cations Sc
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.